Tango Therapeutics, Inc.: FARALLON CAPITAL MANAGEMENT, L.L.C. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Farallon Capital Management amended its Schedule 13G filing on Tango Therapeutics, updating its disclosed stake in the biotech company. The filing, submitted under SEC accession number 0000908834-26-000536, reflects the investment firm's revised position. The amendment signals a change in Farallon's holdings, though the filing did not specify the size or direction of the adjustment. Investors watch 13G amendments for clues about institutional conviction in small-cap biotech names like Tango. Further detail on the exact share count and percentage owned would clarify whether Farallon increased or trimmed its exposure.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Farallon Capital Management, L.L.C., Tango Therapeutics, Inc.